» Articles » PMID: 39060412

Comparative Network-based Analysis of Toll-like Receptor Agonist, L-pampo Signaling Pathways in Immune and Cancer Cells

Overview
Journal Sci Rep
Specialty Science
Date 2024 Jul 26
PMID 39060412
Authors
Affiliations
Soon will be listed here.
Abstract

Toll-like receptors (TLRs) are critical components to stimulate immune responses against various infections. Recently, TLR agonists have emerged as a promising way to activate anti-tumor immunity. L-pampo, a TLR1/2 and TLR3 agonist, induces humoral and cellular immune responses and also causes cancer cell death. In this study, we investigated the L-pampo-induced signals and delineated their interactions with molecular signaling pathways using RNA-seq in immune cells and colon and prostate cancer cells. We first constructed a template network with differentially expressed genes and influential genes from network propagation using the weighted gene co-expression network analysis. Next, we obtained perturbed modules using the above method and extracted core submodules from them by conducting Walktrap. Finally, we reconstructed the subnetworks of major molecular signals utilizing a shortest path-finding algorithm, TOPAS. Our analysis suggests that TLR signaling activated by L-pampo is transmitted to oxidative phosphorylation (OXPHOS) with reactive oxygen species (ROS) through PI3K-AKT and JAK-STAT only in immune and prostate cancer cells that highly express TLRs. This signal flow may further sensitize prostate cancer to L-pampo due to its high basal expression level of OXPHOS and ROS. Our computational approaches can be applied for inferring underlying molecular mechanisms from complex gene expression profiles.

Citing Articles

m5C methylation modification may be an accomplice in colorectal cancer escaping from anti-tumor effects of innate immunity-type I/III interferon.

Sun Y, Liu Y, Jiang L, Zhong C Front Immunol. 2025; 15:1512353.

PMID: 39867908 PMC: 11757137. DOI: 10.3389/fimmu.2024.1512353.


Regulating Immune Responses Induced by PEGylated Messenger RNA-Lipid Nanoparticle Vaccine.

Jo H, Jeoung J, Kim W, Jeoung D Vaccines (Basel). 2025; 13(1).

PMID: 39852793 PMC: 11768904. DOI: 10.3390/vaccines13010014.

References
1.
Pasare C, Medzhitov R . Toll-dependent control mechanisms of CD4 T cell activation. Immunity. 2004; 21(5):733-41. DOI: 10.1016/j.immuni.2004.10.006. View

2.
Marshak-Rothstein A . Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006; 6(11):823-35. PMC: 7097510. DOI: 10.1038/nri1957. View

3.
Rakoff-Nahoum S, Medzhitov R . Toll-like receptors and cancer. Nat Rev Cancer. 2008; 9(1):57-63. DOI: 10.1038/nrc2541. View

4.
Naour J, Kroemer G . Trial watch: Toll-like receptor ligands in cancer therapy. Oncoimmunology. 2023; 12(1):2180237. PMC: 9980677. DOI: 10.1080/2162402X.2023.2180237. View

5.
Lee B, Jeong S, Ahn B, Lee B, Shin S, Yum J . Combination of TLR1/2 and TLR3 ligands enhances CD4(+) T cell longevity and antibody responses by modulating type I IFN production. Sci Rep. 2016; 6:32526. PMC: 5007540. DOI: 10.1038/srep32526. View